Fulcrum Therapeutics, Inc. financial data

Symbol
FULC on Nasdaq
Industry
Pharmaceutical Preparations
Location
26 Landsdowne Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Jul 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.96K % +16.5%
Debt-to-equity 8.73 % -16.6%
Return On Equity -8.28 % +79.1%
Return On Assets -7.61 % +78.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.4M shares +0.94%
Common Stock, Shares, Outstanding 62.3M shares +19.5%
Common Stock, Value, Issued 62K USD 0%
Weighted Average Number of Shares Outstanding, Basic 62K shares +3.79%
Weighted Average Number of Shares Outstanding, Diluted 62K shares +3.79%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 74.3M USD +8.43%
General and Administrative Expense 40.1M USD -3.71%
Operating Income (Loss) -32.8M USD +69.5%
Net Income (Loss) Attributable to Parent -20.2M USD +79.4%
Earnings Per Share, Basic -0.34 USD/shares +80.7%
Earnings Per Share, Diluted -0.36 USD/shares +79.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 86.7M USD +155%
Other Assets, Current 47K USD -81.8%
Assets, Current 280M USD -0.94%
Property, Plant and Equipment, Net 4.41M USD -28.5%
Operating Lease, Right-of-Use Asset 6.36M USD -21.9%
Other Assets, Noncurrent 1.99M USD -0.3%
Assets 294M USD -2.02%
Accounts Payable, Current 3.58M USD -8.31%
Employee-related Liabilities, Current 2.72M USD -7.1%
Liabilities, Current 12.7M USD -14.2%
Operating Lease, Liability, Noncurrent 7.57M USD -21.6%
Other Liabilities, Noncurrent 197K USD -55.9%
Liabilities 20.5M USD -17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -366K USD +69.5%
Retained Earnings (Accumulated Deficit) -481M USD -4.39%
Stockholders' Equity Attributable to Parent 274M USD -0.6%
Liabilities and Equity 294M USD -2.02%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.3M USD -4.84%
Net Cash Provided by (Used in) Financing Activities 1.65M USD -98.6%
Net Cash Provided by (Used in) Investing Activities 38.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 62.3M shares +0.69%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.5M USD
Deferred Tax Assets, Valuation Allowance 130M USD -21.3%
Deferred Tax Assets, Gross 133M USD -20.5%
Depreciation 1.89M USD -19.6%
Payments to Acquire Property, Plant, and Equipment 28K USD -83.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.4M USD +80.3%
Property, Plant and Equipment, Gross 17.9M USD -0.16%
Operating Lease, Liability, Current 2.08M USD -17%
Deferred Tax Assets, Operating Loss Carryforwards 75M USD -12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.19M USD +29.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%